double placebo is one of 2 therapeutic programs targeting Heart Failure Preserved Ejection Fraction. It is currently in Preclinical.
Indications
Total Trials
Active Trials
Competitors
Pipeline
Competition
2 competitors in Heart Failure Preserved Ejection Fraction
Henggliflozin
double placebo
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Sources
Details